Your browser doesn't support javascript.
loading
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes.
Canning, Paul; Kenny, Bridget-Ann; Prise, Vivien; Glenn, Josephine; Sarker, Mosharraf H; Hudson, Natalie; Brandt, Martin; Lopez, Francisco J; Gale, David; Luthert, Philip J; Adamson, Peter; Turowski, Patric; Stitt, Alan W.
Afiliação
  • Canning P; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Royal Victoria Hospital, Belfast, United Kingdom;
  • Kenny BA; Department of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom;
  • Prise V; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Royal Victoria Hospital, Belfast, United Kingdom;
  • Glenn J; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Royal Victoria Hospital, Belfast, United Kingdom;
  • Sarker MH; Department of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom; School of Science & Engineering, Teesside University, Middlesbrough TS1 3BA, United Kingdom;
  • Hudson N; Department of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom;
  • Brandt M; Platform Technology Sciences, GlaxoSmithKline, King of Prussia, PA 19406;
  • Lopez FJ; Ophthalmology Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA 19406;
  • Gale D; Ophthalmology Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA 19406;
  • Luthert PJ; Department of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom;
  • Adamson P; Ophthalmology Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom; Ocular Biology and Therapeutics, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom.
  • Turowski P; Department of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom; a.stitt@qub.ac.uk p.turowski@ucl.ac.uk.
  • Stitt AW; Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Royal Victoria Hospital, Belfast, United Kingdom; a.stitt@qub.ac.uk p.turowski@ucl.ac.uk.
Proc Natl Acad Sci U S A ; 113(26): 7213-8, 2016 06 28.
Article em En | MEDLINE | ID: mdl-27298369
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Barreira Hematorretiniana / 1-Alquil-2-acetilglicerofosfocolina Esterase / Diabetes Mellitus Experimental / Retinopatia Diabética Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Barreira Hematorretiniana / 1-Alquil-2-acetilglicerofosfocolina Esterase / Diabetes Mellitus Experimental / Retinopatia Diabética Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2016 Tipo de documento: Article